Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Huaren Pharmaceutical Co's Median PS Value or its related term are showing as below:
SZSE:300110'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59 Med: 0.68 Max: 0.9
Current: 0.76
During the past 13 years, the highest Price to Median PS Value of Huaren Pharmaceutical Co was 0.90. The lowest was 0.59. And the median was 0.68.
SZSE:300110's Price-to-Median-PS-Value is ranked better than 59.71% of 556
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs SZSE:300110: 0.76
Huaren Pharmaceutical Co (SZSE:300110) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Huaren Pharmaceutical Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.90
/
3.82
=
0.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Huaren Pharmaceutical Co Median PS Value Related Terms
Huaren Pharmaceutical Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Huaren Pharmaceutical Co Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Huaren Pharmaceutical Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.4016.
Huaren Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.123.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Huaren Pharmaceutical Co (SZSE:300110) has a Median PS Value of ¥3.82 as of Aug. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Huaren Pharmaceutical Co and its competitors. According to the industry distribution chart, Huaren Pharmaceutical Co ranks #224 out of 556 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is Huaren Pharmaceutical Co's Median PS Value too high?
Huaren Pharmaceutical Co's current Median PS Value is ¥3.82. Based on the distribution chart, Huaren Pharmaceutical Co ranks #224 out of 556 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Huaren Pharmaceutical Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Huaren Pharmaceutical Co's Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Huaren Pharmaceutical Co ranks #224 out of 556 companies for Median PS Value. This puts Huaren Pharmaceutical Co in the upper half of its industry. The industry median Median PS Value is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Huaren Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Huaren Pharmaceutical Co's current Median PS Value is ¥3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huaren Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co (SZSE:300110) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.13, compared to a current price of ¥2.90 — trading 7.3% below its estimated fair value. The current Median PS Value is ¥3.82. Huaren Pharmaceutical Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Huaren Pharmaceutical Co (SZSE:300110), the current Median PS Value is ¥3.82 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Huaren Pharmaceutical Co (SZSE:300110) Overvalued in 2026?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥2.90 is trading 7.3% below its estimated GF Value™ of ¥3.13.
GuruFocus considers Huaren Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SZSE:300110:
Median PS Value: ¥3.82
GF Value™: ¥3.13 vs. price of ¥2.90 (7.3% below fair value)
No single metric tells the full story. See the SZSE:300110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
55GF Score
Get the complete analysis for SZSE:300110
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300110 has been successfully added to your 
